These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34862459)

  • 1. Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML.
    Nicosia L; Boffo FL; Ceccacci E; Conforti F; Pallavicini I; Bedin F; Ravasio R; Massignani E; Somervaille TCP; Minucci S; Bonaldi T
    Oncogene; 2022 Feb; 41(6):878-894. PubMed ID: 34862459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
    Barth J; Abou-El-Ardat K; Dalic D; Kurrle N; Maier AM; Mohr S; Schütte J; Vassen L; Greve G; Schulz-Fincke J; Schmitt M; Tosic M; Metzger E; Bug G; Khandanpour C; Wagner SA; Lübbert M; Jung M; Serve H; Schüle R; Berg T
    Leukemia; 2019 Jun; 33(6):1411-1426. PubMed ID: 30679800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia.
    Maiques-Diaz A; Spencer GJ; Lynch JT; Ciceri F; Williams EL; Amaral FMR; Wiseman DH; Harris WJ; Li Y; Sahoo S; Hitchin JR; Mould DP; Fairweather EE; Waszkowycz B; Jordan AM; Smith DL; Somervaille TCP
    Cell Rep; 2018 Mar; 22(13):3641-3659. PubMed ID: 29590629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation.
    Ravasio R; Ceccacci E; Nicosia L; Hosseini A; Rossi PL; Barozzi I; Fornasari L; Zuffo RD; Valente S; Fioravanti R; Mercurio C; Varasi M; Mattevi A; Mai A; Pavesi G; Bonaldi T; Minucci S
    Sci Adv; 2020 Apr; 6(15):eaax2746. PubMed ID: 32284990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
    Przespolewski A; Wang ES
    Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
    Zhang S; Liu M; Yao Y; Yu B; Liu H
    Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.
    Ishikawa Y; Gamo K; Yabuki M; Takagi S; Toyoshima K; Nakayama K; Nakayama A; Morimoto M; Miyashita H; Dairiki R; Hikichi Y; Tomita N; Tomita D; Imamura S; Iwatani M; Kamada Y; Matsumoto S; Hara R; Nomura T; Tsuchida K; Nakamura K
    Mol Cancer Ther; 2017 Feb; 16(2):273-284. PubMed ID: 27903753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
    Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
    Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia.
    Johnston G; Ramsey HE; Liu Q; Wang J; Stengel KR; Sampathi S; Acharya P; Arrate M; Stubbs MC; Burn T; Savona MR; Hiebert SW
    Gene; 2020 Aug; 752():144758. PubMed ID: 32422235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia.
    Deb G; Wingelhofer B; Amaral FMR; Maiques-Diaz A; Chadwick JA; Spencer GJ; Williams EL; Leong HS; Maes T; Somervaille TCP
    Leukemia; 2020 May; 34(5):1266-1277. PubMed ID: 31780813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
    Murray-Stewart T; Woster PM; Casero RA
    Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.
    Braun TP; Coblentz C; Curtiss BM; Coleman DJ; Schonrock Z; Carratt SA; Callahan RL; Maniaci B; Druker BJ; Maxson JE
    Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13670-13679. PubMed ID: 32471953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
    Wen S; Wang J; Liu P; Li Y; Lu W; Hu Y; Liu J; He Z; Huang P
    Cancer Lett; 2018 Jan; 413():35-45. PubMed ID: 29069576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML.
    Vinyard ME; Su C; Siegenfeld AP; Waterbury AL; Freedy AM; Gosavi PM; Park Y; Kwan EE; Senzer BD; Doench JG; Bauer DE; Pinello L; Liau BB
    Nat Chem Biol; 2019 May; 15(5):529-539. PubMed ID: 30992567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
    Duy C; Teater M; Garrett-Bakelman FE; Lee TC; Meydan C; Glass JL; Li M; Hellmuth JC; Mohammad HP; Smitheman KN; Shih AH; Abdel-Wahab O; Tallman MS; Guzman ML; Muench D; Grimes HL; Roboz GJ; Kruger RG; Creasy CL; Paietta EM; Levine RL; Carroll M; Melnick AM
    Cancer Discov; 2019 Jul; 9(7):872-889. PubMed ID: 31076479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural protoberberine alkaloids, identified as potent selective LSD1 inhibitors, induce AML cell differentiation.
    Li ZR; Suo FZ; Guo YJ; Cheng HF; Niu SH; Shen DD; Zhao LJ; Liu ZZ; Maa M; Yu B; Zheng YC; Liu HM
    Bioorg Chem; 2020 Apr; 97():103648. PubMed ID: 32065882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1.
    Carmichael CL; Wang J; Nguyen T; Kolawole O; Benyoucef A; De Mazière C; Milne AR; Samuel S; Gillinder K; Hediyeh-Zadeh S; Vo ANQ; Huang Y; Knezevic K; McInnes WRL; Shields BJ; Mitchell H; Ritchie ME; Lammens T; Lintermans B; Van Vlierberghe P; Wong NC; Haigh K; Thoms JAI; Toulmin E; Curtis DJ; Oxley EP; Dickins RA; Beck D; Perkins A; McCormack MP; Davis MJ; Berx G; Zuber J; Pimanda JE; Kile BT; Goossens S; Haigh JJ
    Blood; 2020 Aug; 136(8):957-973. PubMed ID: 32369597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.
    Schenk T; Chen WC; Göllner S; Howell L; Jin L; Hebestreit K; Klein HU; Popescu AC; Burnett A; Mills K; Casero RA; Marton L; Woster P; Minden MD; Dugas M; Wang JC; Dick JE; Müller-Tidow C; Petrie K; Zelent A
    Nat Med; 2012 Mar; 18(4):605-11. PubMed ID: 22406747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-
    Smitheman KN; Severson TM; Rajapurkar SR; McCabe MT; Karpinich N; Foley J; Pappalardi MB; Hughes A; Halsey W; Thomas E; Traini C; Federowicz KE; Laraio J; Mobegi F; Ferron-Brady G; Prinjha RK; Carpenter CL; Kruger RG; Wessels L; Mohammad HP
    Haematologica; 2019 Jun; 104(6):1156-1167. PubMed ID: 30514804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition.
    Abdel-Aziz AK; Pallavicini I; Ceccacci E; Meroni G; Saadeldin MK; Varasi M; Minucci S
    Haematologica; 2020 Aug; 105(8):2105-2117. PubMed ID: 31537694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.